Science & Technology
Neurotech Announces Publication of NT-501 Phase 2 Results.
Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia.
Neurotech Announces Renewed Focus on NT-501 (CNTF) Encapsulated Cell Therapy Clinical Programs.
Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implant